Trevi Therapeutics
@trevitherapeutics.com
Trevi is a clinical-stage biopharma company currently developing the investigational oral therapy Haduvio™ (nalbuphine ER) for serious chronic cough conditions.
Trevi Therapeutics's Company Logos
Trevi Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#8E8E8E
Gray
142, 142, 142
0, 0, 56
0, 0, 0, 44
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#002E4D
Prussian Blue
0, 46, 77
204, 100, 15
100, 40, 0, 70
About Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious chronic cough conditions. Their investigational therapy, Haduvio™ (oral nalbuphine ER), targets both the central and peripheral nervous systems to provide relief to patients suffering from chronic cough. With a commitment to patients, Trevi Therapeutics is currently investigating Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
They have already achieved positive results from their Phase 2 CANAL trial and are preparing to initiate the next clinical trial for IPF patients. Founded in 2011 and headquartered in New Haven, CT, Trevi Therapeutics is proud to be part of the vibrant life-science community. They are dedicated to making a difference in patients' lives through their passionate team and their focus on improving chronic cough conditions, including interstitial lung diseases and refractory chronic cough.
To learn more about Trevi Therapeutics and their groundbreaking therapy, Haduvio, visit their website
Company type
Privately Held
Year founded
2011
Company size
11-50 employees
